TVRD Tvardi Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1346830 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-12.7%
TTM EPS YoY64.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-123.1%
ROA-85.2%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets34.3%
Debt / equity0.00x
Current ratio2.86x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.02x
Accruals ratio1.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | $2.57M | $1.46M |
| R&D expense | $4.47M | $4.00M | $4.91M | $5.49M | $3.60M | $5.81M | $3.11M | $8.60M |
| SG&A expense | $1.85M | $2.63M | $2.14M | $2.10M | $2.33M | $3.06M | $1.24M | $2.20M |
| Operating income | -$6.33M | -$6.63M | -$7.05M | -$7.59M | -$5.94M | -$8.87M | -$4.35M | -$10.80M |
| Interest expense | — | — | — | — | $0 | $93,000 | $558,000 | — |
| Income tax | — | — | — | — | — | — | $0 | -$398,000 |
| Net income | -$6.12M | -$6.46M | -$6.80M | -$7.28M | -$5.53M | $4.17M | -$9.58M | -$12.71M |
| EBITDA | -$6.30M | -$6.61M | -$7.03M | -$7.56M | -$5.91M | -$8.82M | -$4.33M | -$10.78M |
| EPS (basic) | -0.48 | -0.69 | -0.73 | — | -0.59 | 0.51 | -3.72 | — |
| EPS (diluted) | -0.48 | -0.69 | -0.73 | — | -0.59 | -1.00 | -3.72 | — |
| Dividends declared per share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
| Weighted avg. shares (diluted) | 12.65M | 9.38M | 9.38M | — | 9.38M | 8.46M | 2.58M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $22.27M | $15.77M | $19.85M | $20.73M | $21.42M | $20.65M | $11.44M | $31.61M |
| Short-term investments | $0 | — | $5.13M | $10.08M | $15.04M | $20.35M | — | — |
| Receivables | — | — | — | — | — | — | $1.23M | $407,000 |
| Inventory | — | — | — | — | — | — | $900,000 | $900,000 |
| Current assets | $23.13M | $17.07M | $25.33M | $31.54M | $38.44M | $43.13M | — | $31.69M |
| PP&E, net | $28,000 | $36,000 | $44,000 | $52,000 | $60,000 | $68,000 | — | $84,000 |
| Intangibles | $275,000 | $291,000 | $306,000 | $322,000 | $338,000 | $354,000 | — | $385,000 |
| Total assets | $23.53M | $17.52M | $25.82M | $32.07M | $39.02M | $43.75M | $38.95M | $35.20M |
| Current liabilities | $8.08M | $9.11M | $11.26M | $11.04M | $11.04M | $10.68M | $1.20M | $10.37M |
| Total liabilities | $8.08M | $9.13M | $11.31M | $11.13M | $11.15M | $10.82M | $47.02M | $40.83M |
| Shareholders' equity | $15.46M | $8.38M | $14.51M | $20.95M | $27.87M | $32.93M | -$100.62M | -$91.13M |
| Shares outstanding | 13.35M | 9.38M | 9.38M | 9.38M | 9.38M | 9.37M | 1.52M | 2.57M |
| Cash flow statement | ||||||||
| Operating cash flow | -$6.38M | -$9.23M | -$5.86M | -$5.68M | -$4.26M | -$8.87M | -$7.69M | -$4.83M |
| Capital expenditure | — | — | — | — | — | — | — | $0 |
| Free cash flow | — | — | — | — | — | — | — | -$4.83M |
| Investing cash flow | $0 | $5.14M | $4.98M | $5.00M | $5.35M | -$9.55M | -$10.88M | $5.00M |
| Financing cash flow | — | — | — | $1,000 | -$322,000 | $22.02M | -$1.60M | $27.01M |
| Depreciation & amortization | $24,000 | $23,000 | $24,000 | $24,000 | $24,000 | $47,000 | $24,000 | $24,000 |
| Stock-based compensation | $386,000 | $335,000 | $370,000 | $353,000 | $339,000 | $627,000 | $80,000 | $79,000 |
Free plan shows the latest 8 periods; Pro shows all 55 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.